Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 3
2011 2
2012 8
2013 13
2014 3
2015 4
2016 9
2017 15
2018 9
2019 6
2020 9
2021 15
2022 9
2023 9
2024 11
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.
Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre-Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Mohty M, Leleu X, Manier S, Mariette C, Chaleteix C, Braun T, De Prijck B, Avet-Loiseau H, Mary JY, Corre J, Moreau P, Touzeau C; MIDAS Study Group. Perrot A, et al. N Engl J Med. 2025 Jul 31;393(5):425-437. doi: 10.1056/NEJMoa2505133. Epub 2025 Jun 3. N Engl J Med. 2025. PMID: 40459097 Clinical Trial.
Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial.
Perrot A, Touzeau C, Lambert J, Hulin C, Caillot D, Karlin L, Arnulf B, Rey P, Garderet L, Macro M, Escoffre Barbe M, Gay J, Chalopin T, Gounot R, Schiano JM, Tiab M, Mohty M, Kuhnowski F, Fontan J, Manier S, Orsini-Piocelle F, Vincent L, Rigaudeau S, Leleu X, Hebraud B, Flet L, Malfuson JV, Jacquet C, Chaoui D, Meuleman N, Abarah W, Montes L, Benramdane R, Sonntag C, Zerazhi H, Danu A, Allangba O, Dib M, Roussel M, Cereja S, Depaus J, Branche N, Demarquette H, Richez V, Cherel B, Frenzel L, Vekemans MC, Bigot N, Avet-Loiseau H, Corre J, Moreau P. Perrot A, et al. Among authors: danu a. Blood. 2025 Jul 3;146(1):52-61. doi: 10.1182/blood.2024026230. Blood. 2025. PMID: 39841461 Clinical Trial.
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO's pharmacovigilance database.
Morice PM, Khalife-Hachem S, Sassier M, Lelong-Boulouard V, Danu A, Pasquier F, Renneville A, Dolladille C, Micol JB. Morice PM, et al. Among authors: danu a. Blood Cancer J. 2024 Oct 14;14(1):177. doi: 10.1038/s41408-024-01154-z. Blood Cancer J. 2024. PMID: 39402057 Free PMC article. No abstract available.
Infectious Complications in Patients Treated with T-cell Engagers as Cancer Immunotherapies, A Descriptive Study from the REISAMIC Registry.
Hueso T, Cagnat J, Ouali K, Haberstich M, Henry B, Danu A, Bigenwald C, Merad M, Messayke S, Laparra A, Sakkal M, Smolenschi C, Hollebecque A, Gazzah A, Baldini C, Bahleda R, Besse B, Rigaud C, Minard-Colin V, Ribrag V, Laghouati S, Chachaty E, Barlesi F, Marabelle A, Lambotte O, Massard C, Michot JM. Hueso T, et al. Among authors: danu a. Clin Infect Dis. 2025 Apr 1:ciaf164. doi: 10.1093/cid/ciaf164. Online ahead of print. Clin Infect Dis. 2025. PMID: 40165410
Investigational drugs for T-cell lymphoma.
Ghez D, Danu A, Ribrag V. Ghez D, et al. Among authors: danu a. Expert Opin Investig Drugs. 2016;25(2):171-81. doi: 10.1517/13543784.2016.1121994. Epub 2015 Dec 17. Expert Opin Investig Drugs. 2016. PMID: 26576861 Review.
[Hodgkin lymphoma: Current and future therapeutic strategies].
Turpin A, Michot JM, Kempf E, Mazeron R, Dartigues P, Terroir M, Boros A, Bonnetier S, Castilla-Llorente C, Coman T, Danu A, Ghez D, Pilorge S, Arfi-Rouche J, Dercle L, Soria JC, Carde P, Ribrag V, Fermé C, Lazarovici J. Turpin A, et al. Among authors: danu a. Bull Cancer. 2018 Jan;105(1):81-98. doi: 10.1016/j.bulcan.2017.11.008. Epub 2017 Dec 27. Bull Cancer. 2018. PMID: 29289336 Review. French.
Cell-free DNA sequencing as a potential screening tool for phase I targeted treatment in refractory/relapse diffuse large B-cell lymphoma.
Quivoron C, Tarabay A, Michot JM, Pagès A, Lecourt H, Aupérin A, Danu A, Lazarovici J, Rossignol J, Ghez D, Dartigues P, Vergé V, Massard C, Camara-Clayette V, Ribrag V, Sarkozy C. Quivoron C, et al. Among authors: danu a. Haematologica. 2022 Aug 1;107(8):1928-1932. doi: 10.3324/haematol.2021.280464. Haematologica. 2022. PMID: 35320922 Free PMC article. No abstract available.
First Measurement of A=4 Hypernuclei and Antihypernuclei at the LHC.
Acharya S, Agarwal A, Aglieri Rinella G, Aglietta L, Agnello M, Agrawal N, Ahammed Z, Ahmad S, Ahn SU, Ahuja I, Akindinov A, Akishina V, Al-Turany M, Aleksandrov D, Alessandro B, Alfanda HM, Alfaro Molina R, Ali B, Alici A, Alizadehvandchali N, Alkin A, Alme J, Alocco G, Alt T, Altamura AR, Altsybeev I, Alvarado JR, Alvarez COR, Anaam MN, Andrei C, Andreou N, Andronic A, Andronov E, Anguelov V, Antinori F, Antonioli P, Apadula N, Aphecetche L, Appelshäuser H, Arata C, Arcelli S, Arnaldi R, Arneiro JGMCA, Arsene IC, Arslandok M, Augustinus A, Averbeck R, Averyanov D, Azmi MD, Baba H, Badalà A, Bae J, Baek YW, Bai X, Bailhache R, Bailung Y, Bala R, Balbino A, Baldisseri A, Balis B, Banoo Z, Barbasova V, Barile F, Barioglio L, Barlou M, Barman B, Barnaföldi GG, Barnby LS, Barreau E, Barret V, Barreto L, Bartels C, Barth K, Bartsch E, Bastid N, Basu S, Batigne G, Battistini D, Batyunya B, Bauri D, Bazo Alba JL, Bearden IG, Beattie C, Becht P, Behera D, Belikov I, Bell Hechavarria ADC, Bellini F, Bellwied R, Belokurova S, Beltran LGE, Beltran YAV, Bencedi G, Bensaoula A, Beole S, Berdnikov Y, Berdnikova A, Bergmann L, Besoiu MG, Betev L, Bhaduri PP, Bhasin A, Bhattacharjee B, Bianchi L… See abstract for full author list ➔ Acharya S, et al. Among authors: danu a. Phys Rev Lett. 2025 Apr 25;134(16):162301. doi: 10.1103/PhysRevLett.134.162301. Phys Rev Lett. 2025. PMID: 40344112
Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.
Khalife-Hachem S, Pages A, Akoury E, Bonnet S, Birsen R, Busquet C, Contejean A, Danu A, de Botton S, de Charette M, Dumas PY, Jaccard A, Marfaing-Koka A, Willekens C, Deconinck E, Ghez D. Khalife-Hachem S, et al. Among authors: danu a. Blood Adv. 2025 Feb 25;9(4):793-796. doi: 10.1182/bloodadvances.2024014590. Blood Adv. 2025. PMID: 39642332 Free PMC article. No abstract available.
121 results